Free Pick from Jeff Brown: “Buy S.C.G .”
Jeff Brown picked Tesla in 2018 before it jumped 1,390%. He picked Nvidia before it jumped 3,545%. And he picked Bitcoin before it skyrocketed 22,750%.

And now he’s saying S.C.G. will be the next big tech play. He’s not the only one. Apple’s CEO even called it “the next big thing.”
Click here and get the name and ticker symbol!
Michael D. Goldberg, insider at CareDx
Michael D. Goldberg Insider Alerts

Get notified the next time Michael D. Goldberg buys or sells CareDx stock. Enter your email address below to get our daily insider buying and selling report.

Michael D. Goldberg Insider Information

Director of CareDx
Michael Goldberg has served as a member and chairman of our board of directors since November 2011. From January 2005 to May 2011, Mr. Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular diagnostics, personalized medicine, and wireless healthcare. From October 2000 to December 2004, Mr. Goldberg operated a management and financial consultancy business. In 1995, Mr. Goldberg founded OnCare, Inc., an oncology disease management company, and served as chairman until August 2001 and as chief executive officer until March 1999. In 1987, Mr. Goldberg founded Axion, Inc., a cancer treatment services company, and served as chief executive officer until its sale to Bristol-Myers Squibb in 1995. Prior to Axion, Mr. Goldberg was a partner at the venture capital firm, Sevin Rosen Management Company, from 1985 to 1987, where he established the firm’s life science practice, and was director of corporate development at Cetus Corporation from 1981 to 1985. Mr. Goldberg has served as a member of the board of directors of numerous companies in the biotech and health sciences industry, and currently serves as executive chairman of DNAnexus, Inc. Mr. Goldberg has served on boards and advisory boards of a number of industry, academic, and public policy institutions in biotechnology and finance, including the board of the Independent Citizens Oversight Committee, which is the governing board for the California Institute for Regenerative Medicine, the board of the Western Association of Venture Capitalists, the advisory boards of the Harvard Center for Genetics and Genomics, the Berkeley Center for Law and Technology, and the UCSF Center for Translational and Policy Research on Personalized Medicine. Mr. Goldberg holds a BA from Brandeis University and an MBA from the Stanford Graduate School of Business.

What is Michael D. Goldberg's net worth?

The estimated net worth of Michael D. Goldberg is at least $2.74 million as of May 10th, 2021. Mr. Goldberg owns 73,945 shares of CareDx stock worth more than $2,738,183 as of January 22nd. This net worth estimate does not reflect any other investments that Mr. Goldberg may own. Learn More.

How do I contact Michael D. Goldberg?

The corporate mailing address for Mr. Goldberg and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected]

Has Michael D. Goldberg been buying or selling shares of CareDx?

During the last ninety days, Michael D. Goldberg has sold $21,485.00 of CareDx stock. Most recently, Michael Goldberg sold 500 shares of the business's stock in a transaction on Monday, January 10th. The shares were sold at an average price of $42.97, for a transaction totalling $21,485.00.

Who are CareDx's active insiders?

CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director).

Are insiders buying or selling shares of CareDx?

In the last twelve months, CareDx insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $211,700.00. In the last twelve months, insiders at the sold shares 37 times. They sold a total of 416,378 shares worth more than $25,658,229.05. The most recent insider tranaction occured on January, 18th when insider Reginald Seeto sold 1,719 shares worth more than $68,880.33. Insiders at CareDx own 4.6 % of the company.

Information on this page was last updated on 1/18/2022.

Michael D. Goldberg Insider Trading History at CareDx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2022Sell500$42.97$21,485.00View SEC Filing Icon  
12/9/2021Sell500$45.41$22,705.00View SEC Filing Icon  
11/9/2021Sell500$47.54$23,770.00View SEC Filing Icon  
10/11/2021Sell500$62.50$31,250.00View SEC Filing Icon  
5/10/2021Sell15,442$68.94$1,064,571.4873,945View SEC Filing Icon  
12/14/2020Sell30,000$70.19$2,105,700.0071,784View SEC Filing Icon  
5/11/2020Sell10,000$29.86$298,600.0080,765View SEC Filing Icon  
3/14/2019Sell50,000$37.36$1,868,000.0084,740View SEC Filing Icon  
7/22/2014Buy25,000$10.00$250,000.00View SEC Filing Icon  
See Full Table

Michael D. Goldberg Buying and Selling Activity at CareDx

This chart shows Michael Goldberg's buying and selling at CareDx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CareDx Company Overview

CareDx logo
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $37.03
Low: $36.47
High: $38.50

50 Day Range

MA: $43.06
Low: $37.03
High: $47.50

2 Week Range

Now: $37.03
Low: $36.47
High: $96.88


1,020,688 shs

Average Volume

808,920 shs

Market Capitalization

$1.96 billion

P/E Ratio


Dividend Yield



[FREE Report] 5 Growth Stocks Under $49
Stay focused on the long-term with these 5 growth stock picks.
Learn More.